Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
- 24 June 2015
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 7 (293) , 293ra102
Abstract
Epigenetic drugs can overcome resistance to monoclonal antibodies in T-PLL and activate therapeutic targets for antibody-drug conjugates.Keywords
Funding Information
- National Cancer Institute (RO1-CA098472)
- Lymphoma Research Foundation
- Chemotherapy Foundation
- Leukemia and Lymphoma Society
- Gabrielle's Angel Foundation
- Paul Calabresi Career Development (K12-CA132783-01)
- Tobacco Settlement funds of PA
This publication has 64 references indexed in Scilit:
- Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL PatientsScience Translational Medicine, 2012
- Brentuximab vedotinNature Reviews Drug Discovery, 2012
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsImmunology & Cell Biology, 2011
- Primary Cutaneous CD30-Positive Large T-Cell Lymphoma in an 80-Year-Old Man: A Case ReportISRN Dermatology, 2011
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphomaBlood, 2010
- A pipeline for the quantitative analysis of CG dinucleotide methylation using mass spectrometryBioinformatics, 2009
- Critical Role for Transcription Factor C/EBP-β in Regulating the Expression of Death-Associated Protein Kinase 1Molecular and Cellular Biology, 2008
- Enhanced TLR-mediated NF-IL6–dependent gene expression by Trib1 deficiencyJournal of Experimental Medicine, 2007
- Comparative isoschizomer profiling of cytosine methylation: The HELP assayGenome Research, 2006
- Targeting histone deacetylase in cancer therapyMedicinal Research Reviews, 2006